Completed PHASE3 INTERVENTIONAL 1-arm NCT00235872

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis

Sponsor: Abbott

Interventions adalimumab

Updated 6 times since 2017 Last updated: Apr 7, 2011 Started: Aug 31, 2004 Primary completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Rheumatoid Arthritis and is currently completed. Abbott leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Abbott Japan Co.,Ltd
Eisai Co., Ltd.

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Chiba, Japan , Ehime, Japan , Fukui, Japan , Fukuoka, Japan , Gunma, Japan , Hokkaido, Japan , Hyōgo, Japan , Ibaraki, Japan , Ishikawa, Japan and 15 more locations